Phase 2Completed
A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
An Exploratory, Open-label, Non-randomized, Within-patient Multiple Dose-escalation Safety, Tolerability, PK and Efficacy Trial of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
- Sponsor
- Novartis Pharmaceuticals (Industry)
- Enrollment
- 24 enrolled
- Conditions
- Lymphangioleiomyomatosis
- Interventions
- Everolimus
- Ages
- adults, older adults
- Registry
- NCT01059318, EUCTR2010-019825-32
Full record on ClinicalTrials.gov
From the registry
This was an exploratory study to determine whether escalating doses of RAD001 (everolimus) were safe and effective in patients with Lymphangioleiomyomatosis
Primary outcomes
- Change From Baseline in Vascular Endothelial Growth Factor-D (VEGF-D) Concentrations
- Mean Trough (C0,ss) and Peak (C2,ss) Drug Concentration at Steady State
History
Results first posted
Last registry update
Primary completion
Registered
Started